Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Academic Drug Discovery


The Discovery and Development of E209 - a Tetraoxane Based Rapidly Acting Antimalarial

Gemma Nixon, Lecturer, University of Liverpool

Endoperoxide antimalarial drug development has been a key component of the Medicinal Chemistry Group’s activities at the University of Liverpool for the last 15 years. Here we describe the drug discovery programme that has delivered a synthetic tetraoxane-based molecule, E209, which meets key requirements of the Medicines for Malaria Venture drug candidate profiles. E209 has potent nanomolar inhibitory activity against multiple strains of P. falciparum and P. vivax in vitro, is efficacious against P. falciparum in in vivo rodent models, produces parasite reduction ratios equivalent to dihydroartemisinin and has pharmacokinetic and pharmacodynamic characteristics compatible with a single-dose cure. K13 gene mutations are a primary marker of artemisinin resistance in Plasmodium falciparum malaria that threatens the long-term clinical utility of artemisinin-based combination therapies, the cornerstone of modern day malaria treatment. In vitro studies of E209 with transgenic parasites expressing variant forms of K13 show no cross-resistance with the C580Y mutation, the primary variant observed in Southeast Asia. E209 is a superior next generation endoperoxide with combined pharmacokinetic and pharmacodynamic features that overcome the liabilities of artemisinin derivatives.

Add to Calendar ▼2017-03-06 00:00:002017-03-07 00:00:00Europe/LondonAcademic Drug